ABIVAX SA (ABVX.PA) Stock Price & Overview
EPA:ABVX • FR0012333284
The current stock price of ABVX.PA is 98.9 EUR. Today ABVX.PA is down by -0.6%. In the past month the price increased by 4.63%. In the past year, price increased by 1253.74%.
ABVX.PA Key Statistics
- Market Cap
- 7.82B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.80
- Dividend Yield
- N/A
ABVX.PA Stock Performance
ABVX.PA Stock Chart
ABVX.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ABVX.PA. When comparing the yearly performance of all stocks, ABVX.PA is one of the better performing stocks in the market, outperforming 99.76% of all stocks.
ABVX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABVX.PA. ABVX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ABVX.PA Earnings
On December 15, 2025 ABVX.PA reported an EPS of -1.59 and a revenue of 2.09M. The company missed EPS expectations (-0.57% surprise) and missed revenue expectations (-36.06% surprise).
ABVX.PA Forecast & Estimates
14 analysts have analysed ABVX.PA and the average price target is 128.26 EUR. This implies a price increase of 29.69% is expected in the next year compared to the current price of 98.9.
For the next year, analysts expect an EPS growth of -20.7% and a revenue growth 29.38% for ABVX.PA
ABVX.PA Groups
Sector & Classification
ABVX.PA Financial Highlights
Over the last trailing twelve months ABVX.PA reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 18.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABVX.PA Ownership
ABVX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.98 | 39.779B | ||
| ARGX | ARGENX SE | 24.32 | 39.754B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.871B | ||
| 2X1 | ABIVAX SA | N/A | 7.844B | ||
| GLPG | GALAPAGOS NV | N/A | 1.886B | ||
| GXE | GALAPAGOS NV | N/A | 1.883B | ||
| NANO | NANOBIOTIX | N/A | 1.398B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.061B | ||
| PHIL | PHILOGEN SPA | 16.81 | 615.502M | ||
| GNFT | GENFIT | N/A | 431.775M | ||
| AYJ | VALNEVA SE | N/A | 408.046M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ABVX.PA
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
ABIVAX SA / ABVX.PA FAQ
What does ABVX do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the stock price of ABIVAX SA today?
The current stock price of ABVX.PA is 98.9 EUR. The price decreased by -0.6% in the last trading session.
Does ABIVAX SA pay dividends?
ABVX.PA does not pay a dividend.
How is the ChartMill rating for ABIVAX SA?
ABVX.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ABVX stock?
ABVX.PA stock is listed on the Euronext Paris exchange.
Is ABIVAX SA (ABVX.PA) expected to grow?
The Revenue of ABIVAX SA (ABVX.PA) is expected to grow by 29.38% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does ABIVAX SA (ABVX.PA) report earnings?
ABIVAX SA (ABVX.PA) will report earnings on 2026-03-23, after the market close.